McMillan Shakespeare Ltd (ASX: MMS) and Eclipx Group Ltd (ASX: ECX) have both released statements to the ASX officially calling an end to the proposed merger.
What Was It All About?
The Eclipx-McMillan merger was originally touted as a “compelling combination” of two complementary businesses. The plan was to combine Eclipx’s operating lease business with McMillan’s salary packaging and novated businesses.
The two companies announced this would generate approximately $50 million in EBITDA run-rate synergies per annum to be realised within three years.
They also expected to see future growth potential from an expanded customer base, increased liquidity and access to capital.
Since being announced, the Eclipx share price has been battered, down 70% over the last six months.
Cracks Started To Show
As McMillan looked further into the Eclipx balance sheet, issues started to arise. Late last month, McMillan released a statement saying, “we do not believe it will be possible to complete the proposed scheme.”
The issues highlighted by McMillan were:
- A decline in Eclipx NPATA of 42.4% compared to the first five months of FY18
- “Significant” issues with the Right2Drive and Grays divisions
- Impact of process errors which Eclipx has identified on past financial years
- Eclipx no longer expects to meet FY19 earnings guidance provided on 29th January 2019
- Eclipx was unable to provide revised FY19 earnings guidance
McMillan shares rose on this announcement while Eclipx tanked.
It’s Official — They’ve Broken It Off
Both companies have confirmed today that the merger will not be going ahead.
McMillan’s Chief Financial Officer Mark Blackburn said that McMillan and Eclipx, “have today agreed to terminate the Scheme Implementation Agreement dated 8 November 2018 (SIA) with immediate effect and to release one another from any claims relating to the SIA and the proposed scheme.”
Blackburn also announced that Eclipx has agreed to reimburse McMillan for costs incurred in relation to the SIA, amounting to $8 million. Eclipx stated that this will be funded from operating cash flow.
McMillan shares traded 1.3% lower following the announcement, while Eclipx shares end down 2.5%.
Forget McMillan and Eclipx, if you’re looking for ASX shares that are far more reliable and growing quickly, consider getting a copy of our free investing report below…
After searching through a market with over 2,000 shares, our lead expert investment analyst has narrowed it down to just 2 of his favourite rapid-growth shares in a FREE report to Rask Media readers.
Over the past five years, these two shares have gone from being 'tiny caps' to being serious contenders for the ASX 200.
Idea #1 is taking on the world, starting with the huge USA market. In a just a few short years the company has snatched market share away from rivals and is on its way to being the market leader.
Idea #2 uses a 'printer and cartridge' type model to get large and established customers: a) using their healthcare industry-leading product, b) paying for it again and again and again... so it's little wonder this company is tipped to grow at a rapid pace in 2019.
Access the free report by clicking here now. Absolutely no credit card or payment details required.
Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).
Disclaimer: At the time of writing, Max does not own shares in any of the companies mentioned.